Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Shire    SHP   JE00B2QKY057


News SummaryMost relevantAll newsSector newsTweets 

Shire Plc. : Shire Buying Pervasis To Advance Regenerative Medicines Business

share with twitter share with LinkedIn share with facebook
share via e-mail
04/12/2012 | 05:49pm CEST
  By Sten Stovall 

Shire PLC (SHP.LN) is buying the assets of U.S.-based Pervasis Therapeutics in a deal that brings a new technology aimed at improving blood vessel repair for dialysis patients to the U.K. drug maker's regenerative medicine business.

A specialist in hyperactivity and rare genetic diseases, Shire is also expanding its activities in regenerative medicine to find products for replacing human cells, tissues or organs to restore or establish normal function.

Toward that end, Shire on Thursday said it will pay Pervasis an undisclosed upfront payment, plus milestones if Pervasis' lead product, a cell-based therapy called Vascugel, hits certain clinical, regulatory and sales targets. No financial terms were disclosed.

Pervasis, based in Cambridge, Massachusetts, is developing acute vascular repair technologies for patients with end-stage renal disease, or ESRD, which is an advanced and irreversible kidney disease. There are around 600,000 people in the U.S. and more than 250,000 in the EU currently being treated for ESRD.

Shire said its deal with Pervasis will make a strong strategic fit with its existing Dermagraft treatment for diabetic foot ulcers.

Diabetes is the chief cause of ESRD, while diabetic patients on dialysis have a greater risk of developing a diabetic foot ulcer than diabetics not receiving dialysis treatment.

Shire's head of regenerative medicine, Kevin Rakin, said that "this acquisition marks a very important step for Shire in building a regenerative medicine business focused on tissue repair and regeneration."

He told Dow Jones Newswires that Vascugel is currently in mid-stage clinical trials and will be progressing to late-stage Phase III testing soon. Vascugel has received Orphan Product designation from the U.S. Food and Drug Administration and from the European Medical Agency. If all goes well, marketing authorization could be sought for Vascugel by 2017, Rakin said.

Pervasis will give Shire a new cell-based technology platform called endothelial cell technology that has global potential. "We are looking at generating other products out of this platform," Rakin said.

"We're building our regenerative medicine activities because we believe it's one of the next big areas of medicine and so this adds to the Dermagraft purchase and we're building up our pipeline now. We're committed to doing this."

- By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SHIRE
06/23 SHIRE : To present new data at isth 2017 to advance the standard of care in hemo..
06/22 SHIRE : FDA approves new Shire drug for ADHD
06/22 SHIRE : announces EMA validation of VEYVONDI™ Marketing Authorization Appl..
06/21 SHIRE PLC : Financial Statements and Exhibits (form 8-K)
06/21 SHIRE : U.S. FDA Approves Mydayis™ (mixed salts of a single-entity ampheta..
06/09 SHIRE : New Therapeutics Research Study Results Reported from Shire Pharmaceutic..
06/07 FTSE slips as markets brace for election
06/01 SHIRE PLC (NASDAQ : SHPG) Files An 8-K Other Events
06/01 SHIRE PLC : Financial Statements and Exhibits (form 8-K)
More news
Sector news : Pharmaceuticals - NEC
01:10pDJMERCK AND : Today's Top Supply Chain and Logistics News From WSJ
08:35a Factbox - Companies hit by global ransomware attack on June 27
06/27DJMERCK AND : Says Its Network Was Hit by Global Hack
06/26DJASTRAZENECA : ADRs End Mostly Higher
06/26 VALEANT PHARMACEUTICALS INTL : Hedge fund Paulson & Co discloses 6.3 percent sta..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/27 DOVA PHARMACEUTICALS : A Different Business Model Could Lead To Success
06/27 Q3 BIOTECH CATALYST WATCH : Phase 2 Data Releases (Part 1)
06/26 Roche Brings New Blood To Hemophilia A
06/23 Biocryst and Shire under pressure on FDA approval of Behring's HAE med
06/23 FDA OKs Behring's Haegarda to prevent HAE attacks
Financials ($)
Sales 2017 15 102 M
EBIT 2017 5 644 M
Net income 2017 2 575 M
Debt 2017 18 765 M
Yield 2017 0,65%
P/E ratio 2017 17,22
P/E ratio 2018 12,77
EV / Sales 2017 4,70x
EV / Sales 2018 4,15x
Capitalization 52 190 M
More Financials
Duration : Period :
Shire Technical Analysis Chart | SHP | JE00B2QKY057 | 4-Traders
Full-screen chart
Technical analysis trends SHIRE
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 73,3 $
Spread / Average Target 27%
Consensus details
EPS Revisions
More Estimates Revisions
Flemming Ornskov Chief Executive Officer & Executive Director
Susan Saltzbart Kilsby Non-Executive Chairman
Jeffrey Poulton Chief Financial Officer & Executive Director
Philip J. Vickers Global Head-Research & Development
Matt Walker Head-Technical Operations
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE-3.50%52 190
JOHNSON & JOHNSON18.34%363 694
ROCHE HOLDING LTD.8.21%224 549
NOVARTIS12.55%222 848
PFIZER3.97%201 105
MERCK AND COMPANY11.33%179 263
More Results